Anti-cancer stem cell drug starts clinical trials
Upcoming SlideShare
Loading in...5
×
 

Anti-cancer stem cell drug starts clinical trials

on

  • 2,348 views

 

Statistics

Views

Total Views
2,348
Views on SlideShare
2,157
Embed Views
191

Actions

Likes
1
Downloads
74
Comments
2

4 Embeds 191

http://npstemcells.wikispaces.com 181
http://cursos.itesm.mx 7
https://npstemcells.wikispaces.com 2
https://blackboard.montclair.edu 1

Accessibility

Categories

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Anti-cancer stem cell drug starts clinical trials Anti-cancer stem cell drug starts clinical trials Presentation Transcript

  • Anti-cancer stem cell drug starts clinical trials By: Vito Randazzo OncoMed Pharmaceuticals Inc., is currently developing therapeutic drugs that target cancer stem cells. The dosing and study for effectiveness of the drug has commenced in a Phase 1 clinical trial of OMP-59R5 in patients with advanced solid tumor cancers.
  • What does the company OncoMed Pharmaceuticals do?
    • The company is a leader in cancer stem cell research.
    • OncoMed Pharmaceuticals is a clinical-stage company that discovers and develops novel therapeutics targeting cancer stem cells, which are the cells believed to be capable of driving tumor growth.
    • The company has established a variety of antibodies to cancer stem cell proteins for the treatment of solid tumors for pancreatic, breast, colorectal and lung cancer patients.
  • How does the drug work?
    • OMP-59R5 is a monoclonal antibody that binds selected Notch receptors in cancerous tumors called cancer stem cells.
    • The drug’s purpose is to improve cancer treatment by targeting the key biologic pathways in cancerous growths, such as Notch receptors, which are believed to be critical to the activity and survival of tumors.
    • This is the first drug of its kind to ever reach a clinical trial in humans.
  •  
  • What does OMP-59R5 do?
    • OMP-59R5 is designed to treat cancer by targeting tumor-initiating cells and receptors.
    • These tumor initiating cells are also known as cancer stem cells, which are a small subset of cells that are found in all tumors.
    • These cells have the potential to self-renew and differentiate which can drive the tumors growth and metastasis.
    • OMP-59R5 is designed to drastically decrease the amount of tumor-initiating cells and receptors in a tumor.
  • Where is the drug now?
    • This drug has commenced in a Phase 1 clinical trial in patients with advanced solid tumors in a variety of different cancers.
    • The success of these types of monoclonal antibodies in the past have varied greatly, however preliminary results from this study showed a positive indication of disease control and tumor responses to the drug.
  • What has the drug succeeded in so far?
    • The Phase 1 Clinical trial, being conducted at leading U.S. cancer treatment centers, has demonstrated a decrease in the frequency of tumor-initiating cells in patients with a variety of tumor types.
    • Preliminary results from this study show positive indications of disease control and tumor responses to the drug.
  • Are there any side effects of the drug?
    • No side effects from the clinical trials currently being undergone have been reported.
    • This does not mean that the drug is 100% safe till all phases of the clinical trial are complete.
    • The results so far show a positive direction to tumor treatment using this monoclonal antibody.
  • How much research is there on OMP-595R?
    • In December 2007, OncoMed Pharmaceuticals and GSK agreed on a partnership valued at over $1.4 billion to develop cancer stem cell monoclonal antibodies targeting Notch signaling pathways of tumors.
    • Over three years of research has lead to this breakthrough discovery.
  • What potential does OMP-59R5 have?
    • Depending on the success of this Phase 1 clinical trial of OMP-59R5, stem cell trials such such as OncoMed Pharmaceutical’s, could be the future for this type of research.
    • The advancement of this monoclonal antibody into clinical trials represents an important milestone for OncoMed, proving their productive drug discovery capabilities, and for possible new and improved drugs being produced in the future.